From Wikipedia, the free encyclopedia
 |
|
Ixabepilone
|
| Systematic (IUPAC) name |
(1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-1,5,7,
9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol-
4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0]
heptadecane-8,12-dione |
| Identifiers |
| CAS number |
219989-84-1 |
| ATC code |
L01DC04 |
| PubChem |
6445540 |
| Chemical data |
| Formula |
C27H42N2O5S |
| Mol. mass |
506.698 g/mol |
| SMILES |
eMolecules & PubChem |
| Synonyms |
Azaepothilone B |
| Pharmacokinetic data |
| Bioavailability |
N/A |
| Protein binding |
67 to 77% |
| Metabolism |
Extensive, hepatic, CYP3A4-mediated |
| Half life |
52 hours |
| Excretion |
Fecal (mostly) and renal |
| Therapeutic considerations |
| Pregnancy cat. |
D(US)
|
| Legal status |
℞-only(US)
|
| Routes |
Intravenous infusion |
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.
On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. ([1]). Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra.
As of January 2008, ixabepilone is not yet available in the European Union.
[edit] Clinical uses
Ixabepilone is indicated, in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane.
[edit] External links
|
Chemotherapeutic agents/Antineoplastic agents (L01) |
|
| Alkylating and alkylating-like agents |
Nitrogen mustards: ( Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Bendamustine, Uramustine)
Nitrosoureas:(Carmustine, Fotemustine, Lomustine, Streptozocin)
Platinum (alkylating-like): (Carboplatin, Cisplatin, Oxaliplatin, Triplatin tetranitrate, Satraplatin)
Alkyl sulfonates:(Busulfan, Treosulfan)
Hydrazines:(Procarbazine, Dacarbazine, Temozolomide)
Aziridines:( ThioTEPA)
|
|
| Antimetabolites |
Folic acid: ( Aminopterin, Methotrexate, Pemetrexed, Raltitrexed)
Purine: (Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Pentostatin, Thioguanine)
Pyrimidine: ( Cytarabine, Decitabine, Fluorouracil/ Capecitabine, Floxuridine, Gemcitabine)
|
|
| Spindle poison/mitotic inhibitor |
|
|
| Cytotoxic/antitumor antibiotics |
|
|
| Topoisomerase inhibitors |
|
|
| CI monoclonal antibodies |
|
|
| Photosensitizers |
|
|
| Tyrosine kinase inhibitors |
Axitinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, Vandetanib
|
|
| Cyclin-dependent kinase inhibitor |
|
|
| Other |
retinoids ( Alitretinoin, Tretinoin), Fusion protein ( Aflibercept) - Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase ( Pegaspargase), Bexarotene, Bortezomib, Celecoxib, Denileukin diftitox, Elesclomol, Estramustine, Irofulven, Ixabepilone, Masoprocol, Mitotane, Oblimersen, Testolactone, Tipifarnib, Trabectedin
|
|
